Patent Assignment
Reel/Frame 052795/0074
Intellectual Property Security Agreement
Recorded: 2020-05-29
Pages: 42
Assignor
G1 THERAPEUTICS, INC.
Executed: 2020-05-29
Assignee
HERCULES CAPITAL, INC., AS COLLATERAL AGENT
400 HAMILTON AVENUE, SUITE 310, PALO ALTO, CALIFORNIA, 94301
Covered Properties
(101)
Cdk Inhibitors
Cdk Inhibitors
Cdk Inhibitors
Protection of Renal Tissues from Ischemia Through Inhibition of the Proliferative Kinases CDK4 and CDK6
Cdk Inhibitors
Cdk Inhibitors
Transient Protection of Normal Cells During Chemotherapy
Transient Protection of Normal Cells During Chemotherapy
HSPC-Sparing Treatments for RB-Positive Abnormal Cellular Proliferation
Synthesis of Lactams
CDK Inhibitors
Lactam Kinase Inhibitors
Tricyclic Lactams for Use in HSPC-Sparing Treatments for RB-Positive Abnormal Cellular Proliferation
CDK Inhibitors
CDK Inhibitors
Lactam Kinase Inhibitors
Transient Protection of Normal Cells During Chemotherapy
Transient Protection of Normal Cells During Chemotherapy
CDK Inhibitors
Lactam Kinase Inhibitors
Benzothiophene-Based Selective Estrogen Receptor Downregulators
HSPC-Sparing Treatments for RB-Positive Abnormal Cellular Proliferation
Anti-Neoplastic Combinations and Dosing Regimens Using CDK4/6 Inhibitor Compounds to Treat Rb-Positive Tumors
Tricyclic Lactams for Use in Hspc-Sparing Treatments for Rb-Positive Abnormal Cellular Proliferation
Lactam Kinase Inhibitors
Benzothiophene Estrogen Receptor Modulators
CDK Inhibitors
Cdk Inhibitors
Cdk Inhibitors
Transient Protection of Normal Cells During Chemotherapy
Transient Protection of Normal Cells During Chemotherapy
Hspc-Sparing Treatments for Rb-Positive Abnormal Cellular Proliferation
Treatment of Rb-Negative Tumors Using Topoisomerase Inhibitors in Combination with Cyclin Dependent Kinase 4/6 Inhibitors
Benzothiophene-Based Selective Estrogen Receptor Downregulators
Hspc-Sparing Treatments for Rb-Positive Abnormal Cellular Proliferation
Benzothiophene Estrogen Receptor Modulators
Cdk Inhibitors
Synthesis of Lactams
Highly Active Anti-Neoplastic and Anti-Proliferative Agents
Synthesis of N-(Heteroaryl)-Pyrrolo[3,2-D]Pyrimidin-2-Amines
Antiproliferative Pyrimidine-Based Compounds
SUBSTITUTED DIHYDROPYRAZINO[1',2':1,5]PYRROLO[2,3-d]PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS
Pyrimidine-Based Compounds for the Treatment of Cancer
Anti-Neoplastic Combinations and Dosing Regimens Using CDK4/6 Inhibitor Compounds to Treat Rb-Positive Tumors
Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
Application:
16/268,317 →
Publication:
US 2019/0167691
Benzothiophene-Based Selective Mixed Estrogen Receptor Downregulators
Benzothiophene-Based Selective Estrogen Receptor Downregulator Compounds
Preservation of Immune Response During Chemotherapy Regimens
Combination Therapy for Treatment of Cancer
Benzothiophene-Based Selective Estrogen Receptor Downregulators
Treatment of Egfr-Driven Cancer with Fewer Side Effects
Treatment of Rb-Negative Tumors Using Topoisomerase Inhibitors in Combination with Cyclin Dependent Kinase 4/6 Inhibitors
Morphic Forms of G1T38 and Methods of Manufacture Thereof
Benzothiophene Estrogen Receptor Modulators
Pyrimidine-Based Compounds for the Treatment of Cancer
Application:
16/847,426 →
Publication:
US 2020/0239486
Cyclin-Dependent Kinase Inhibitors
Application:
61/406,498 →
Kinase Inhibitors
Application:
61/617,657 →
Transient Protection of Normal Cells During Chemotherapy
Application:
61/798,772 →
Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
Application:
61/800,214 →
Pyrazinopyrrolopyrimidines For Use As Anti-Neoplastic Agents
Application:
61/861,374 →
Pyrazinopyrrolopyrimidines For Use As Anti-Neoplastic Agents
Application:
61/911,354 →
HSPC-Sparing Treatments for RB-Positive Abnormal Cellular Proliferation
Application:
61/949,786 →
Highly Active Anti-Neoplastic and Anti-Proliferative Agents
Application:
61/949,795 →
Tricyclic Lactams for Use in HSPC-Sparing Treatments for RB-Positive Abnormal Cellular Proliferation
Application:
61/980,918 →
Treatment of RB-Negative Tumors Using Topoisomerase Inhibitors in Combination with Cyclin Dependent Kinase 4/6 Inhibitors
Application:
62/050,035 →
Anti-Neoplastic Combinations and Dosing Regimens Using CDK4/6 Inhibitor Compounds to Treat RB-Positive Tumors
Application:
62/050,043 →
Benzothiophene-Based Selective Estrogen Receptor Downregulators
Application:
62/264,971 →
Benzothiophene-Based Selective Estrogen Receptor Downregulators
Application:
62/322,878 →
Antiproliferative Pyrimidine-Based Compounds
Application:
62/357,516 →
Pyrimidine-Based Antiproliferative Agents
Application:
62/357,630 →
Synthesis of N-(Heteroaryl)-Pyrrolo [3,2-D] Pyrimidin-2-Amines
Application:
62/357,797 →
Pyrimidine-Based Compounds for the Treatment of Cancer
Application:
62/357,818 →
Novel Benzothiophene-Based Selective Estrogen Receptor Downregulators and Mixed Function Downregulators
Application:
62/411,988 →
Enhanced Priming of an Anti-Cancer Immune Response Using Highly Selective CDK4/6 Inhibitors
Application:
62/430,302 →
Combination Therapy for the Treatment of Cancer
Application:
62/443,588 →
Benzothiophene Estrogen Receptor Modulators
Application:
62/457,643 →
Benzothiophene Estrogen Receptor Modulators
Application:
62/460,358 →
Reversing Acquired Resistance In EGFR-Mutated Non-Small Cell Lung Carcinoma
Application:
62/462,094 →
Enhanced Priming of an Anti-Cancer Immune Response Using Highly Selective CDK4/6 Inhibitors
Application:
62/479,605 →
Morphic Forms of GIT38 and Methods of Manufacture Thereof
Application:
62/526,937 →
Pyrimidine-Based Compounds for the Treatment of Neoplastic Disorders
Application:
62/613,727 →
Benzothiophene Estrogen Receptor Modulators
Application:
62/614,279 →
G1T38 Superior Dosage Regimes
Application:
62/614,952 →
Treatment of Cancers Having Driving Oncogenic Mutations Using Selective Combination Therapies
Application:
62/655,135 →
Treatment of Cancers Having Driving Oncogenic Mutations Using Selective Combination Therapies
Application:
62/657,373 →
Cdk Inhibitors for the Treatment of Neoplastic Disorders
Application:
62/672,474 →
G1T38 Superior Dosage Regimes
Application:
62/679,575 →
Synthesis of 1,4-Diazaspiro[5.5]Undecan-3-One
Application:
62/722,675 →
Eribulin and Selective CDK4/6 Inhibitor Combinations
Application:
62/758,388 →
Benzothiophene estrogen receptor modulators to treat medical disorders
Application:
62/764,757 →
G1T38 Superior Dosage Regimes
Application:
62/788,017 →
Treatment of Cancers Having Driving Oncogenic Mutations Using Selective Combination Therapies
Application:
62/788,024 →
Treatment of Cancers Having Driving Oncogenic Mutations Using Selective Combination Therapies
Application:
62/810,802 →
Treatment of CDK4/6 Inhibitor Resistant Neoplastic Disorders
Application:
62/827,692 →
Cdk Inhibitors for the Treatment of Neoplastic Disorders
Application:
62/827,696 →
Cell Cycle Inhibiting Compounds for the Treatment of Neoplastic Disorders
Application:
62/827,703 →
Survival in Triple Negative Breast Cancer
Application:
62/863,153 →
Cell Cycle Inhibiting Compounds for the Treatment of Neoplastic Disorders
Application:
62/870,351 →
Treatment of CDK4/6 Inhibitor Resistant Neoplastic Disorders
Application:
62/870,357 →
Means for Enhancement of Anti-Tumor Immunity in Cancer Patients
Application:
62/907,375 →
Targeted Treatment of Cancers with Mutations of the Fibroblast Growth Factor Receptor
Application:
62/913,055 →
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Jun 28, 2013
From: SHARPLESS, NORMAN E.; STRUM, JAY C.; BISI, JOHN E.; ROBERTS, PATRICK J.
To: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
Reel/Frame 030708/0305 →
Assignment of Assignor's Interest
Jun 28, 2013
From: DIROCCO, DEREK P.; HUMPHREYS, BENJAMIN D.
To: BRIGHAM AND WOMEN'S HOSPITAL
Reel/Frame 030708/0434 →
Assignment of Assignor's Interest
Jun 28, 2013
From: WONG, KWOK-KIN
To: G1 THERAPEUTICS
Reel/Frame 030708/0584 →
Confirmatory License
Aug 14, 2013
From: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 031013/0604 →
Assignment of Assignor's Interest
May 9, 2016
From: STRUM, JAY C; TAVARES, FRANCIS X
To: G1 THERAPEUTICS, INC.
Reel/Frame 038521/0815 →
Assignment of Assignor's Interest
May 9, 2016
From: STRUM, JAY C; TAVARES, FRANCIS X
To: G1 THERAPEUTICS, INC.
Reel/Frame 038521/0595 →
Assignment of Assignor's Interest
May 9, 2016
From: STRUM, JAY C; TAVARES, FRANCIS X
To: G1 THERAPEUTICS, INC.
Reel/Frame 038521/0678 →
Assignment of Assignor's Interest
May 9, 2016
From: STRUM, JAY C; TAVARES, FRANCIS X
To: G1 THERAPEUTICS, INC.
Reel/Frame 038521/0747 →
Assignment of Assignor's Interest
May 9, 2016
From: STRUM, JAY C; TAVARES, FRANCIS X
To: G1 THERAPEUTICS, INC.
Reel/Frame 038521/0943 →
Assignment of Assignor's Interest
May 9, 2016
From: STRUM, JAY C; TAVARES, FRANCIS X
To: G1 THERAPEUTICS, INC.
Reel/Frame 038521/0917 →
Assignment of Assignor's Interest
May 9, 2016
From: STRUM, JAY C; TAVARES, FRANCIS X
To: G1 THERAPEUTICS, INC.
Reel/Frame 038521/0901 →
Assignment of Assignor's Interest
May 9, 2016
From: STRUM, JAY C; TAVARES, FRANCIS X
To: G1 THERAPEUTICS, INC.
Reel/Frame 038521/0836 →
Assignment of Assignor's Interest
May 26, 2016
From: STRUM, JAY COPELAND; BISI, JOHN EMERSON; ROBERTS, PATRICK JOSEPH; TAVARES, FRANCIS XAVIER
To: G1 THERAPEUTICS, INC.
Reel/Frame 038731/0864 →
Assignment of Assignor's Interest
May 26, 2016
From: STRUM, JAY COPELAND; BISI, JOHN EMERSON; ROBERTS, PATRICK JOSEPH; TAVARES, FRANCIS XAVIER
To: G1 THERAPEUTICS, INC.
Reel/Frame 038730/0019 →
Assignment of Assignor's Interest
Jun 6, 2016
From: BISI, JOHN EMERSON; ROBERTS, PATRICK JOSEPH; STRUM, JAY COPELAND; TAVARES, FRANCIS XAVIER
To: G1 THERAPEUTICS, INC.
Reel/Frame 038889/0833 →
Assignment of Assignor's Interest
Jun 9, 2016
From: STRUM, JAY COPELAND; BISI, JOHN EMERSON; ROBERTS, PATRICK JOSEPH; TAVARES, FRANCIS XAVIER
To: G1 THERAPEUTICS, INC.
Reel/Frame 038870/0078 →
Assignment of Assignor's Interest
Jul 1, 2016
From: TAVARES, FRANCIS XAVIER
To: G1 THERAPEUTICS, INC.
Reel/Frame 039241/0450 →
Assignment of Assignor's Interest
Jul 1, 2016
From: TAVARES, FRANCIS XAVIER
To: G1 THERAPEUTICS, INC.
Reel/Frame 039241/0434 →
Assignment of Assignor's Interest
Jul 10, 2016
From: STRUM, JAY COPELAND; BISI, JOHN EMERSON; ROBERTS, PATRICK JOSEPH
To: G1 THERAPEUTICS, INC.
Reel/Frame 039115/0797 →
Assignment of Assignor's Interest
Jul 10, 2016
From: GASTON, RICKY D.; GADWOOD, ROBERT C.
To: KALEXSYN, INC.
Reel/Frame 039115/0792 →
Assignment of Assignor's Interest
Jul 10, 2016
From: KALEXSYN, INC.
To: G1 THERAPEUTICS, INC.
Reel/Frame 039115/0782 →
Assignment of Assignor's Interest
Oct 7, 2016
From: STRUM, JAY COPELAND; BISI, JOHN EMERSON; ROBERTS, PATRICK JOSEPH; TAVARES, FRANCIS XAVIER
To: G1 THERAPEUTICS, INC.
Reel/Frame 039969/0097 →
Assignment of Assignor's Interest
Mar 19, 2021
From: BISI, JOHN EMERSON; ROBERTS, PATRICK JOSEPH; STRUM, JAY COPELAND; TAVARES, FRANCIS XAVIER
To: G1 THERAPEUTICS, INC.
Reel/Frame 055655/0693 →
Assignment of Assignor's Interest
Mar 19, 2021
From: STRUM, JAY COPELAND; BISI, JOHN EMERSON; ROBERTS, PATRICK JOSEPH
To: G1 THERAPEUTICS, INC.
Reel/Frame 055650/0951 →
Assignment of Assignor's Interest
Mar 19, 2021
From: BISI, JOHN EMERSON; ROBERTS, PATRICK JOSEPH; STRUM, JAY COPELAND; TAVARES, FRANCIS XAVIER
To: G1 THERAPEUTICS, INC.
Reel/Frame 055655/0463 →